Programmed death-1 (PD-1) inhibition with pembrolizumab led to durable remission in 31.3% of patients with early acute ...

Schrödinger is abandoning its CDC7 inhibitor after the therapy was linked to the deaths of two patients in a phase 1 leukemia trial. The biotech had been evaluating the asset, dubbed SGR-2921, in an ...

Schrödinger (Nasdaq: SDGR) has halted the clinical development of its oral drug SGR-2921 following the occurrence of two ...

Third Patient Treated with HG-CT-1 CAR-T Therapy and Completion of First Adult Dose Cohort LONDON, UNITED KINGDOM / ACCESS ...

Amir Fathi, MD, leukemia specialist at Massachusetts General Hospital, discusses the importance of advocacy by both patients ...

Completed the acquisition of Kineta, Inc. and its VISTA inhibiting monoclonal antibody (mAb), now named "TBS-2025;" planning to initiate a Phase 2 trial in relapsed/refractory ...

Schrodinger discontinued its study of a potential treatment for acute myeloid leukemia or high-risk myelodysplastic syndromes, citing patient deaths linked to the treatment.

Schrödinger is discontinuing the development of its blood cancer CDC7 inhibitor after two patient deaths. In a Phase I trial ...

Investing.com -- Schrodinger Inc (NASDAQ:SDGR) stock plunged 13.7% after the company announced it is discontinuing the clinical development program for its CDC7 inhibitor SGR-2921, which was being ...

There's been a major decrease in blood donations, due to many people being away for the summer, which is why non-profit ...

After two patients who received the investigational CDC7 blocker died, pushing forward with SGR-2921’s development would be ...

PM ET HOUSTON, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a ...